Douglas Pharmaceuticals, New Zealand's largest developer and manufacturer of generic pharmaceuticals, is targeting annual revenues of $244 million by 2020 from $145 million today as it seeks higher risk, higher reward opportunities in novel drug development.
The Auckland-based company said growing exports was also critical to meeting the target, set
